NCT05234554Phase 3Completed

The INVIGORATE 2 Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis

Study sponsor: Aldeyra Therapeutics, Inc. · ALDX

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2023-04-22Actual

Enrollment · participants131Actual

Source updated2026-05-14Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-04-23 · 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Compare wording

− Before

Measure: Ocular ~~itching~~ ~~evaluated~~ by the ~~Subject.~~

+ After

Measure: Subject-Reported Ocular Itching Score Assessed in the Allergy Chamber

Check registry source

Study details

Conditions studied

Allergic Conjunctivitis

Treatments or interventions studied

Reproxalap Ophthalmic Solution (0.25%)Drug
Vehicle Ophthalmic SolutionDrug

Primary outcomes · main study measures

Read the study measures

measure: Subject-Reported Ocular Itching Score Assessed in the Allergy Chamber; description: The method of assessment was a 9-point ocular itch scale measured in half-unit increments (0 none - 4 severe) with a higher score representing worse symptomology. Subjects were dosed once just prior to allergen chamber entry and again halfway through the chamber. The allergen chamber was 210 ten minutes in duration with the itching assessment being collected every 10 minutes from 110 to 210 minutes. The timepoints were assessed using mixed model repeated measures.; timeFrame: 110 to 210 minutes during allergen chamber exposure

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history